This Micro Cap Continues This Week's Dominance Amid New CEO Appointment

By: Tomas Ronolski - AllPennyStocks.com News

Thursday, March 20, 2025

A London-based healthcare company found a massive amount of success on Thursday after the company announced that it had appointed a new CEO. The new executive is Abizer Gaslightwala, who was most recently senior vice president and franchise head for US Oncology at Jazz Pharmaceuticals.

Traders loved the new appointment as they pushed shares of Akari Therapeutics Plc (Nasdaq:AKTX) up to $1.73/share (+38.4%) at the early session high. This move was a strong continuation of this week’s success, and could potentially lead to a breakout.

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom.

Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.